Mechanistic Hypotheses (Research-Only Context) Though unproven in humans, AOD-9604 continues to attract scientific curiosity as a model peptide for studying metabolic regulation
Results from a phase 3 trial of semaglutide in patients with fatty liver disease (medically known as metabolic dysfunction-associated steatohepatitis or MASH) found the drug could halt and even reverse the condition, which affects one in five UK adults
Using education, coaching and evidence-based advice, we connect, motivate and empower members to take charge of their health
Participants were randomized 2:1:1:1:1:2:2 to receive placebo or retatrutide at 1 mg, 4 mg (starting at 2 mg), 4 mg (starting at 4 mg), 8 mg (starting at 2 mg), 8 mg (starting at 4 mg), or 12 mg (starting at 2 mg) administered subcutaneously once weekly for 48 weeks
Whichever path you take: always ask for a COA (Certificate of Analysis - the lab report that verifies the product contains what it claims, at the right dose)
Buyer Takeaway: Compounded GLP-1 medications may be prepared using the same active pharmaceutical ingredients as name-brand versions, but they are not the same finished products and are not FDA-approved
